[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:serine-threonine-protein-kinase-chk2":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Serine\u002FThreonine-Protein Kinase Chk2",19,13,[8,16,22,29,35,41,47,53,59,65,71,77,83,89,96,102,108,115,121],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05011383","High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers",[12],"Phase 2","RECRUITING","2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.925238Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06844383","A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.708217Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06177171","Olaparib and ASTX727 in BRCA1\u002F2- and Homologous Recombination Deficient (HRD)-Mutated Tumors",[26],"Phase 1","2026-08-26T02:17:22.949982Z","2026-05-05T02:43:27.676733Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT03786796","Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations",[12],"2026-08-26T02:18:38.077159Z","2026-05-05T02:35:31.766251Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer",[12],"2026-08-26T02:17:39.048487Z","2026-07-19T19:36:05.126907Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",[12],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:26.724920Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05384535","Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort",[],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:28.342933Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT03396341","Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes",[],"2026-08-26T02:16:12.203827Z","2026-07-05T05:32:16.770025Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT07645391","Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:16:05.813655Z","2026-06-14T18:39:22.265063Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT07076147","Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer",[],"2026-08-26T02:19:06.150683Z","2026-05-13T02:55:06.650047Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT07038785","Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs",[],"2026-08-26T02:18:38.865010Z","2026-05-13T02:55:06.608906Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT05129605","Prostate Cancer Genetic Risk Evaluation and Screening Study",[],"2026-08-26T02:18:25.327036Z","2026-05-13T02:55:06.292506Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT03805919","Men at High Genetic Risk for Prostate Cancer",[],"2026-08-26T02:15:18.897219Z","2026-05-13T02:55:06.177945Z",{"nct_id":90,"title":91,"phases":92,"status":93,"updated_at":94,"content_modified":95},"NCT07499999","Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:14.341106Z","2026-05-05T02:43:29.045552Z",{"nct_id":97,"title":98,"phases":99,"status":93,"updated_at":100,"content_modified":101},"NCT07723651","[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)",[12],"2026-08-26T02:19:11.399072Z","2026-07-24T01:27:14.924205Z",{"nct_id":103,"title":104,"phases":105,"status":93,"updated_at":106,"content_modified":107},"NCT07690852","Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care",[],"2026-08-26T02:16:24.970704Z","2026-07-19T19:36:05.153122Z",{"nct_id":109,"title":110,"phases":111,"status":112,"updated_at":113,"content_modified":114},"NCT06212583","High-Risk Metachronous Oligometastatic Prostate Cancer Trial",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:25:31.771325Z","2026-05-05T02:43:29.167176Z",{"nct_id":116,"title":117,"phases":118,"status":112,"updated_at":119,"content_modified":120},"NCT05498272","Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations",[12],"2026-08-03T02:05:27.322885Z","2026-05-05T02:43:27.674415Z",{"nct_id":122,"title":123,"phases":124,"status":112,"updated_at":125,"content_modified":126},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[12],"2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]